1.28

0.78% -0.01

Lineage Cell Therapeutics Inc (LCTX)

Overview News Price History Option Chain Discussions Forecast Stock Split

Lineage Cell Therapeutics Inc stock is traded at $1.28, with a volume of 738.76K. It is down -0.78% in the last 24 hours and up +4.07% over the past month. Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

Previous Close:

$1.29

Open:

$1.29

24h Volume:

738.76K

Relative Volume:

0.49

Market Cap:

$319.10M

Revenue:

$14.78M

Net Income/Loss:

$-64.01M

P/E Ratio:

-4.4553

EPS:

-0.2873

Net Cash Flow:

$-22.59M

1W Performance:

-5.19%

1M Performance:

+4.07%

6M Performance:

-25.15%

1Y Performance:

+25.49%

1-Day Range:

$1.25

$1.30

1-Week Range:

$1.25

$1.38

52-Week Range:

$0.9296

$2.09

Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile

Name

Lineage Cell Therapeutics Inc

Sector

Healthcare (1096)

Industry

Biotechnology (616)

Phone

510-871-4188

Address

2173 Salk Avenue, Suite 200, Carlsbad, CA

Employee

Twitter

@LineageCell

Next Earnings Date

2026-08-11

Latest SEC Filings

LCTX's Discussions on Twitter

Compare LCTX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LCTX Lineage Cell Therapeutics Inc	1.28	319.10M	14.78M	-64.01M	-22.59M	-0.2873
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-20-24	Initiated	Craig Hallum	Buy
Nov-02-22	Initiated	Robert W. Baird	Outperform
Jun-14-22	Initiated	B. Riley Securities	Buy
Aug-19-21	Initiated	Noble Capital Markets	Outperform
Mar-31-21	Initiated	Cantor Fitzgerald	Overweight

Lineage Cell Therapeutics Inc Stock (LCTX) Latest News

Jul 06, 2026

Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit - BioSpace

Jul 06, 2026

Jul 05, 2026

Price to book forward of Lineage Cell Therapeutics, Inc. – AMEX:LCTX - TradingView

Jul 05, 2026

Price to sales forward of Lineage Cell Therapeutics, Inc. – AMEX:LCTX - TradingView

Jul 05, 2026

Jul 03, 2026

LCTX Q1 2026 Earnings: EPS Misses Estimates Despite Positive Stock ReactionShare Dilution Risk - dars.gov.et

Jul 03, 2026

Jul 02, 2026

LCTXLineage Cell Therapeutics Inc Stock Price and Quote - Finviz

Jul 02, 2026

Form 4 Lineage Cell Therapeutics Inc For: 2 July By Investing.com - Investing.com India

Jul 02, 2026

Lineage Cell (LCTX) director granted 125,000 options at $1.30 strike - Stock Titan

Jul 02, 2026

Lineage Cell Therapeutics (LCTX) director receives 125,000 stock options at $1.30 - Stock Titan

Jul 02, 2026

Lineage Cell Therapeutics (LCTX) director awarded 125,000 stock options at $1.30 - Stock Titan

Jul 02, 2026

Lineage Cell Therapeutics (LCTX) director granted 125,000 options at $1.30 strike - Stock Titan

Jul 02, 2026

Jul 01, 2026

Transcript: Lineage Cell Therapeutics Q1 2026 Earnings Conference Call - Benzinga

Jul 01, 2026

Jun 29, 2026

Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026

Lineage Cell Therapeutics, Inc.(NYSEAM: LCTX) added to Russell 2000 Index - marketscreener.com

Jun 29, 2026

Lineage Cell Therapeutics, Inc.(NYSEAM: LCTX) added to Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026

Lineage Cell Therapeutics, Inc.(NYSEAM: LCTX) added to Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026

Lineage Cell Therapeutics, Inc.(NYSEAM: LCTX) added to Russell 3000E Index - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) added to Russell 3000E Growth Benchmark - marketscreener.com

Jun 28, 2026

Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) added to Russell Microcap Growth Benchmark Index - marketscreener.com

Jun 28, 2026

Jun 27, 2026

Price to book forward of Lineage Cell Therapeutics, Inc. – LSX:A2PP89 - TradingView

Jun 27, 2026